MX2021013220A - Metodos para reducir la tasa de actividad de hidrolisis enzimatica en una composicion obtenida de una plataforma de purificacion. - Google Patents

Metodos para reducir la tasa de actividad de hidrolisis enzimatica en una composicion obtenida de una plataforma de purificacion.

Info

Publication number
MX2021013220A
MX2021013220A MX2021013220A MX2021013220A MX2021013220A MX 2021013220 A MX2021013220 A MX 2021013220A MX 2021013220 A MX2021013220 A MX 2021013220A MX 2021013220 A MX2021013220 A MX 2021013220A MX 2021013220 A MX2021013220 A MX 2021013220A
Authority
MX
Mexico
Prior art keywords
methods
reducing
composition obtained
enzymatic hydrolysis
hydrolysis activity
Prior art date
Application number
MX2021013220A
Other languages
English (en)
Inventor
Michael Leiss
Christian Meyer
Alexandra Thomas Morris
Bernhard Spensberger
Yinges Yigzaw
Franziska Edelmann
Roberto Falkenstein
Tobias Graf
Jie Gu
Jeevan Prabhakar
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2021013220A publication Critical patent/MX2021013220A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/20—Partition-, reverse-phase or hydrophobic interaction chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/22—Affinity chromatography or related techniques based upon selective absorption processes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/32—Bonded phase chromatography
    • B01D15/325—Reversed phase
    • B01D15/327—Reversed phase with hydrophobic interaction
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/36—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving ionic interaction
    • B01D15/361—Ion-exchange
    • B01D15/362—Cation-exchange
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3804—Affinity chromatography
    • B01D15/3809—Affinity chromatography of the antigen-antibody type, e.g. protein A, G, L chromatography
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D15/00—Separating processes involving the treatment of liquids with solid sorbents; Apparatus therefor
    • B01D15/08—Selective adsorption, e.g. chromatography
    • B01D15/26—Selective adsorption, e.g. chromatography characterised by the separation mechanism
    • B01D15/38—Selective adsorption, e.g. chromatography characterised by the separation mechanism involving specific interaction not covered by one or more of groups B01D15/265 - B01D15/36
    • B01D15/3847—Multimodal interactions
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D39/00—Filtering material for liquid or gaseous fluids
    • B01D39/14—Other self-supporting filtering material ; Other filtering material
    • B01D39/16—Other self-supporting filtering material ; Other filtering material of organic material, e.g. synthetic fibres
    • B01D39/1607—Other self-supporting filtering material ; Other filtering material of organic material, e.g. synthetic fibres the material being fibrous
    • B01D39/1623—Other self-supporting filtering material ; Other filtering material of organic material, e.g. synthetic fibres the material being fibrous of synthetic origin
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D39/00—Filtering material for liquid or gaseous fluids
    • B01D39/14—Other self-supporting filtering material ; Other filtering material
    • B01D39/20—Other self-supporting filtering material ; Other filtering material of inorganic material, e.g. asbestos paper, metallic filtering material of non-woven wires
    • B01D39/2068—Other inorganic materials, e.g. ceramics
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/145—Ultrafiltration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/16—Extraction; Separation; Purification by chromatography
    • C07K1/165—Extraction; Separation; Purification by chromatography mixed-mode chromatography
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/34—Extraction; Separation; Purification by filtration, ultrafiltration or reverse osmosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/14—Extraction; Separation; Purification
    • C07K1/36—Extraction; Separation; Purification by a combination of two or more processes of different types
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2239/00—Aspects relating to filtering material for liquid or gaseous fluids
    • B01D2239/06—Filter cloth, e.g. knitted, woven non-woven; self-supported material
    • B01D2239/0604—Arrangement of the fibres in the filtering material
    • B01D2239/0618—Non-woven
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D2315/00—Details relating to the membrane module operation
    • B01D2315/16—Diafiltration
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01D—SEPARATION
    • B01D61/00—Processes of separation using semi-permeable membranes, e.g. dialysis, osmosis or ultrafiltration; Apparatus, accessories or auxiliary operations specially adapted therefor
    • B01D61/14—Ultrafiltration; Microfiltration
    • B01D61/147—Microfiltration
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/10—Immunoglobulins specific features characterized by their source of isolation or production
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Water Supply & Treatment (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Ceramic Engineering (AREA)
  • Geology (AREA)
  • Inorganic Chemistry (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La presente divulgación proporciona plataformas de purificación que comprenden una etapa de filtro de profundidad y/o una etapa de cromatografía de interacción hidrófoba (HIC). En la presente también se divulgan métodos para usar las plataformas de purificación descritas en la presente y composiciones obtenidas a partir de estas, tales como composiciones farmacéuticas.
MX2021013220A 2019-05-03 2020-05-01 Metodos para reducir la tasa de actividad de hidrolisis enzimatica en una composicion obtenida de una plataforma de purificacion. MX2021013220A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962843261P 2019-05-03 2019-05-03
US202062961609P 2020-01-15 2020-01-15
PCT/US2020/031164 WO2020227144A1 (en) 2019-05-03 2020-05-01 Methods of reducing the enzymatic hydrolysis activity rate in a composition obtained from a purification platform

Publications (1)

Publication Number Publication Date
MX2021013220A true MX2021013220A (es) 2021-12-10

Family

ID=70779952

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021013220A MX2021013220A (es) 2019-05-03 2020-05-01 Metodos para reducir la tasa de actividad de hidrolisis enzimatica en una composicion obtenida de una plataforma de purificacion.

Country Status (13)

Country Link
US (1) US20220194980A1 (es)
EP (1) EP3962924A1 (es)
JP (2) JP2022531317A (es)
KR (1) KR20220002581A (es)
CN (1) CN114981286A (es)
AU (1) AU2020268896A1 (es)
BR (1) BR112021021972A2 (es)
CA (1) CA3137116A1 (es)
IL (1) IL287689A (es)
MX (1) MX2021013220A (es)
SG (1) SG11202111938YA (es)
TW (1) TW202108600A (es)
WO (1) WO2020227144A1 (es)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20220135620A1 (en) * 2020-10-30 2022-05-05 Genentech, Inc. Purification platforms for obtaining pharmaceutical compositions having a reduced hydrolytic enzyme activity rate

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3920358A1 (de) 1989-06-22 1991-01-17 Behringwerke Ag Bispezifische und oligospezifische, mono- und oligovalente antikoerperkonstrukte, ihre herstellung und verwendung
DK1136556T3 (da) 1991-11-25 2005-10-03 Enzon Inc Fremgangsmåde til fremstilling af multivalente antigen-bindende proteiner
KR20140022845A (ko) 2011-03-25 2014-02-25 제넨테크, 인크. 신규 단백질 정제 방법
WO2013177118A2 (en) * 2012-05-21 2013-11-28 Abbvie Inc. Novel purification of non-human antibodies using protein a affinity chromatography
US10457976B2 (en) * 2013-11-25 2019-10-29 Seattle Genetics, Inc. Preparing antibodies from CHO cell cultures for conjugation
EP3236772A4 (en) 2014-12-22 2018-10-17 Alexion Pharmaceuticals, Inc. Methods of purifying recombinant proteins
JP7091238B2 (ja) * 2015-08-20 2022-06-27 ジェネンテック， インコーポレイテッド Ｆｋｐａの精製、及び組換えポリペプチドの産生のためのその使用
AR108800A1 (es) * 2016-06-17 2018-09-26 Genentech Inc Purificación de anticuerpos multiespecíficos
EP3497440A1 (en) 2016-08-15 2019-06-19 H. Hoffnabb-La Roche Ag Chromatography method for quantifying a non-ionic surfactant in a composition comprising the non-ionic surfactant and a polypeptide

Also Published As

Publication number Publication date
JP2022531317A (ja) 2022-07-06
CN114981286A (zh) 2022-08-30
BR112021021972A2 (pt) 2021-12-21
CA3137116A1 (en) 2020-11-12
KR20220002581A (ko) 2022-01-06
SG11202111938YA (en) 2021-11-29
IL287689A (en) 2021-12-01
AU2020268896A8 (en) 2021-10-28
US20220194980A1 (en) 2022-06-23
EP3962924A1 (en) 2022-03-09
AU2020268896A1 (en) 2021-09-30
WO2020227144A1 (en) 2020-11-12
JP2024062995A (ja) 2024-05-10
WO2020227144A8 (en) 2021-12-02
TW202108600A (zh) 2021-03-01

Similar Documents

Publication Publication Date Title
TWI265927B (en) Novel compounds as NS3-serine protease inhibitors of hepatitis C virus
MY140710A (en) Novel peptides as ns3-serine protease inhibitors of hepatitis c virus
MY145081A (en) Sulfur compounds as inhibitors of hepatitis c virus ns3 serine protease
WO2007076085A3 (en) Fused pyrimidones and thiopyrimidones, and uses thereof
NO20090596L (no) Antivirale fosfinatforbindelser
WO2005086735A3 (en) Novel bicyclic compounds as modulators of androgen receptor function and method
WO2007092065A3 (en) Compounds and compositions as lxr modulators
WO2005087725A3 (en) Novel compounds as inhibitors of hepatitis c virus ns3 serine protease
WO2005087721A3 (en) Compounds as inhibitors of hepatitis c virus ns3 serine protease
NO20072352L (no) Forbindelser og sammensetninger som inhibitorer av cannabinoidreceptor 1-aktivitet
WO2005012242A3 (en) Substituted benzimidazole-, benztriazole-, and benzimidazolone-o-glucosides
NO20071077L (no) Fosfonatanaloger til HIV-inhibitorforbindelser
WO2002062159A8 (en) Nutraceuticals and methods of obtaining nutraceuticals from tropical crops
TW200607863A (en) Immune modulating compounds from fungi
WO2005077122A3 (en) Compounds and compositions as lxr modulators
MX2022006807A (es) Análogos de rapamicina y usos de estos.
PH12016500320A1 (en) Cyclosporin analogues for preventing or treating hepatitis c
WO2005117543A3 (en) N-sulfonylcarboximidamide apoptosis promoters
CR20220216A (es) Aminas de heteroaril-bifenilo para el tratamiento de enfermedades pd-l1
MX2022012110A (es) Sistemas crispr clase ii tipo ii.
WO2009036204A3 (en) Phase ii detoxification and antioxidant activity
WO2021100029A3 (en) Prodrugs of fulvestrant
MX2021013220A (es) Metodos para reducir la tasa de actividad de hidrolisis enzimatica en una composicion obtenida de una plataforma de purificacion.
WO2007067737A3 (en) Methods and compositions for inhibiting hiv infection
WO2005092878A3 (en) Schweinfurthin analogues